thiamine hydrochloride : A hydrochloride obtained by combining thiamine chloride with one molar equivalent of hydrochloric acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6202 |
| CHEMBL ID | 1200941 |
| CHEBI ID | 49105 |
| SCHEMBL ID | 41101 |
| Synonym |
|---|
| thiamine monohydrochloride |
| berin |
| vitaneuron |
| betalin s |
| thiazolium, monohydrochloride |
| benerva |
| eskaphen |
| thiamol |
| thiamine hydrochloride |
| thiadoxine |
| thiazolium, hydrochloride |
| hybee |
| beatine |
| thiamin chloride |
| bequin |
| slowten |
| vitamin b(sub 1) hydrochloride |
| bithiamin |
| trophite |
| begiolan |
| bedome |
| vitamin b hydrochloride |
| thiaminium chloride hydrochloride |
| vinothiam |
| biuno |
| thiamin hydrochloride |
| bevitine |
| vitamin b(sup1) |
| tiaminal |
| clotiamina |
| thiaminium chloride |
| vetalin s |
| thiamine, hydrochloride |
| metabolin |
| eskapen |
| usaf cb-20 |
| thiavit |
| bevitex |
| vitamin b1 hydrochloride |
| apate drops |
| bivita |
| thiaminal |
| wln: t6n cnj b1 dz e1- at5k csj d2q e1 &q &g &gh |
| tiamidon |
| betabion hydrochloride |
| thiamine dichloride |
| thiamine chloride hydrochloride |
| bethiazine |
| aneurine hydrochloride |
| bewon |
| thiamine, monohydrochloride |
| nsc-36226 |
| bivatin |
| lixa-beta |
| beuion |
| thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethyl, chloride, monohydrochloride |
| thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-, chloride, monohydrochloride |
| ccris 1906 |
| nsc 36226 |
| 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethylthiazolium chloride, monohydrochloride |
| chloride-hydrochloride salt of thiamine |
| thiamine hcl |
| thiamine, chloride, hydrochloride |
| einecs 200-641-8 |
| 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride monohydrochloride |
| thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride, monohydrochloride |
| vitamin b1 hydrochloride (van) |
| fema no. 3322 |
| thiamin dichloride |
| ai3-18993 |
| PRESTWICK_441 |
| NCGC00017013-01 |
| cas-67-03-8 |
| MLS001332448 |
| MLS001332447 |
| smr000875246 |
| 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride hydrochloride |
| CHEBI:49105 , |
| thiamine(2+) dichloride |
| 3-[(4-azaniumyl-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium dichloride |
| 67-03-8 |
| thiamine hydrochloride, meets usp testing specifications |
| thiamine hydrochloride, >=98%, fcc, fg |
| thiamine hydrochloride (b1), analytical standard |
| thiamine hydrochloride, bioreagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture |
| thiamine hydrochloride, reagent grade, >=99% (hplc) |
| thiamine hydrochloride (usp) |
| D02094 |
| thiamine chloride hydrochloride (jp17) |
| thiamine hcl (tn) |
| NCGC00017013-02 |
| thiamini hydrochloridum |
| thiaminum hydrochloricum |
| thiamine chloride, hydrochloride |
| CHEMBL1200941 |
| thymine hydrochloride |
| T0181 |
| HMS1569P04 |
| 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol chloride hydrochloride |
| 2-{3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-5-yl}ethan- 1-ol, chloride, chloride |
| tox21_110736 |
| dtxcid8020622 |
| dtxsid0040622 , |
| S3211 |
| unii-m572600e5p |
| thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-, chloride, hydrochloride (1:1:1) |
| thiamine hydrochloride [usp:jan] |
| m572600e5p , |
| FT-0631293 |
| thiamine hydrochloride [ep impurity] |
| thiamini hydrochloridum [who-ip latin] |
| thymine hydrochloride [who-dd] |
| thiamine hydrochloride [usp monograph] |
| thiaminum hydrochloricum [hpus] |
| thiamine hcl [inci] |
| thiamine hydrochloride [usp-rs] |
| thiamine hydrochloride [ep monograph] |
| vitamin b1 [fhfi] |
| thiamine hydrochloride [vandf] |
| thiamine hydrochloride [mi] |
| thiamine hydrochloride [who-dd] |
| thiamine chloride, hydrochloride [who-ip] |
| thiamine hydrochloride [fcc] |
| thiamine hydrochloride [mart.] |
| thiamine hydrochloride [who-ip] |
| thiamine chloride hydrochloride [jan] |
| thiamine hydrochloride [orange book] |
| AKOS015905506 |
| CCG-220677 |
| SCHEMBL41101 |
| DPJRMOMPQZCRJU-UHFFFAOYSA-M |
| vitamin bl |
| 3-((4-amino-2-methylpyrimidin-5-yl)methyl)-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride hydrochloride |
| F0001-2415 |
| Q-201928 |
| thiamine hcl (vitamin b1) |
| thiazolium,3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methyl- |
| mfcd00012780 |
| 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol;chloride;hydrochloride |
| F2173-0852 |
| thiamine hydrochloride, 99% (dry wt.), may cont. up to 5% water |
| thiamine hydrochloride, saj special grade, >=98.5% |
| thiamine hydrochloride, united states pharmacopeia (usp) reference standard |
| thiamine hydrochloride, tested according to ph.eur. |
| thiamine hydrochloride, p.a., 98% |
| thiamine hydrochloride, pharmaceutical secondary standard; certified reference material |
| thiamine for system suitability, european pharmacopoeia (ep) reference standard |
| thiamine hydrochloride, european pharmacopoeia (ep) reference standard |
| thiamine hydrochloride (vitamin b1) |
| thiamine hydrochloride (vitamin b1) 1.0 mg/ml in methanol (as free base) |
| SY010871 |
| thiamine (hydrochloride) |
| CS-8164 |
| 67-03-8 (hcl salt) |
| vitamin b1 (thiamine hcl) |
| aneurinehydrochloride |
| HY-N0680 |
| Q27121486 |
| thiamine hydrochloride 10 microg/ml in acetonitrile |
| AS-14151 |
| BCP27971 |
| vitamin b1hydrochloride |
| thiamine chloride hydrochloride;vitamin b1 hydrochloride |
| FT-0777960 |
| vitamin b1 hydrochloride hydrate |
| SB57886 |
| thiamine for system suitability |
| 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium hydrochloride chloride |
| EN300-258109 |
| thiamine hydrochloride (ep impurity) |
| 3-((4-azaniumyl-2-methylpyrimidin-5-yl)methyl)-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium dichloride |
| thiamine hydrochloride (usp:jan) |
| thiamine hydrochloride (mart.) |
| thiamine hydrochloride (usp-rs) |
| thiamine hydrochloride (usp monograph) |
| thiamine hydrochloride (ep monograph) |
| Z1954805523 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Role | Description |
|---|---|
| insect repellent | An insecticide that acts as a repellent to insects. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| vitamin B1 | Any member of the group of 1,3-thiazolium cations that exhibit biological activity against vitamin B1 deficiency in animals. Symptoms of vitamin B1 deficiency include constipation, loss of apetite, fatigue, nausea, delirium, blurry vision and muscle weakness. Severe vitamin B1 deficiency can also lead to a disease known as beriberi. Vitamin B1 consists of the vitamer thiamin and its acid, aldehyde and phosphorylated derivatives (and their corresponding ionized, salt and hydrate forms). |
| hydrochloride | A salt formally resulting from the reaction of hydrochloric acid with an organic base. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 7.9433 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 39.8107 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 50.1187 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 10.0000 | 0.0054 | 28.0263 | 1,258.9301 | AID1346985 |
| geminin | Homo sapiens (human) | Potency | 0.4611 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| Vpr | Human immunodeficiency virus 1 | Potency | 28.1838 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 7.7543 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 8.9125 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 14.2999 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 9 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (59.46) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||